

Press release  
30 September 2021

## Curasight warrant TO 1 – last day of trading is Tuesday 5 October 2021

Tuesday, 5 October 2021, is the last day of trading in warrants of series TO 1 on Spotlight Stock Market. The warrant TO 1 was issued in connection with Curasights A/S (“Curasight” or “the Company”) IPO in 2020. The last day to subscribe for shares with the support of warrants of series TO 1 is 7 October 2021.

Warrants of series TO 1 that have not been subscribed for shares by Thursday 7 October 2021 or sold by Tuesday 5 October 2021 will expire and therefore be worthless. The warrant holder needs to take action and instruct their bank in due time, if not already done. It is solely the warrant holders’ responsibility.

Application forms are available for download on Curasight’s website ([Curasight.com](https://www.curasight.com)), Sedermera Fondkommission’s website ([Sedermera.se](https://www.sedermera.se)).

**For further information regarding the warrants of series TO 1, please contact:**

Sedermera Fondkommission  
+46 40 – 615 14 10  
[info@sedermera.se](mailto:info@sedermera.se)  
[www.sedermera.se](https://www.sedermera.se)

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](https://www.curasight.com)

**Curasight A/S** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.